Terns Pharmaceuticals Inc
TERN
Detailliertes Diagramm anzeigen
14.030USD
+5.770+69.85%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.23BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+69.85%
5 Tage
+80.57%
1 Monat
+74.72%
6 Monate
+300.86%
Seit Jahresbeginn
+153.25%
1 Jahr
+102.16%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Terns Pharmaceuticals Inc
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Terns Pharmaceuticals Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
11
Analysten
Kaufen
Aktuelles Rating
15.827
Kursziel
+91.61%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Terns Pharmaceuticals Inc Highlights
HöhepunkteRisiko
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-7.78)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=91.38M, string=20.00%)
institutional_hold%!(EXTRA string=Invesco)
institutional_hold_desc%!(EXTRA string=Invesco, string=73.69K)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Terns Pharmaceuticals Inc Informationen
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
BörsenkürzelTERN
UnternehmenTerns Pharmaceuticals Inc
CEOMs. Amy L. Burroughs
Websitehttps://ternspharma.com/
Verwandte Finanzinstrumente
+0.85%
-2.18%
-2.92%
-18.20%
+0.60%
+2.51%
-1.80%
-0.76%
-0.42%
-1.41%
+0.71%
-0.63%
+0.03%
-1.30%
-1.89%
-1.75%
-1.73%
-2.14%
+0.58%
-2.27%Beliebte Symbole
